Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of RBD1016 in chronic hepatitis D virus infection
2023-509007-33-00Phase 2Authorised
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Mar 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in hepatitis D (HDV) and hepatitis B (HBV) comparing RBD1016 + Vemlidy with Placebo + Vemlidy (2 arms). Planned start Mar 2024; status: authorised.
02
Drugs
RBD1016
03
Conditions
hepatitis D (HDV)hepatitis B (HBV)
Beyond the preview
Go deeper on 2023-509007-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509007-33-00.